Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer
- 8 June 2006
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 98 (1), 20-27
- https://doi.org/10.1111/j.1464-410x.2006.06176.x
Abstract
We review the effectiveness of androgen-deprivation therapy (ADT) in the management of prostate cancer, and the effect that this treatment has on a patient's quality of life (QoL), based on discussions held at a European symposium on the management of prostate cancer. The overall QoL is reduced in asymptomatic men, and there are known decreases in cognitive function, self-esteem, libido and sexual function. Hot flashes are also a frequent problem. Prolonged ADT can lead to osteoporosis and subsequently fractures. Various effective methods exist to manage and minimize these side-effects; some are specific to the side-effect, whereas other more general methods include lifestyle changes, specific drugs and added hormonal manipulations. Intermittent ADT for patients taking luteinizing hormone-releasing hormone agonists offers a promising method to reduce adverse effects, and possibly increases the time to androgen independence. Initial studies indicate that prostate-specific antigen-based progression with intermittent ADT is similar to that seen with continuous ADT, but there is a reduction in side-effects, leading to an improvement in QoL.Keywords
This publication has 76 references indexed in Scilit:
- Long‐term side‐effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II studyBJU International, 2005
- Role of Bisphosphonates in Prostate CancerEuropean Urology, 2004
- The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate CancerJournal of Urology, 2003
- The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapyThe Lancet Oncology, 2003
- Pathophysiology and Treatment of Hot FlashesMayo Clinic Proceedings, 2002
- An investigation into the use of palliative care services by patients with prostate cancerAmerican Journal of Hospice and Palliative Medicine®, 2002
- Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2002
- Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate CancerEuropean Urology, 1998
- Neoadjuvant Androgen Withdrawal Therapy Decreases Local Recurrence Rates Following Tumor Excision in the Shionogi Tumor ModelJournal of Urology, 1997
- Osteoporosis After Orchiectomy for Prostate CancerJournal of Urology, 1997